Cellectar Biosciences (CLRB) Projected to Release Quarterly Earnings on Tuesday

Cellectar Biosciences (NASDAQ:CLRB) is projected to issue its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Cellectar Biosciences to post earnings of ($0.5565) per share and revenue of $17.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.05). On average, analysts expect Cellectar Biosciences to post ($2.39) EPS for the current fiscal year and ($2.08) EPS for the next fiscal year.

Cellectar Biosciences Stock Performance

Shares of NASDAQ CLRB opened at $1.25 on Friday. The company’s fifty day moving average price is $1.75 and its 200 day moving average price is $2.58. Cellectar Biosciences has a 1 year low of $1.11 and a 1 year high of $4.70. The company has a market capitalization of $11.81 million, a PE ratio of -0.33 and a beta of 0.65.

Analyst Ratings Changes

A number of research analysts have weighed in on CLRB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Thursday, October 15th. Wall Street Zen lowered Cellectar Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Brookline Capital Markets raised Cellectar Biosciences to a “strong-buy” rating in a report on Sunday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.00.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics and oncology treatments. Its technology platform uses phospholipid ether compounds, which are designed to preferentially accumulate in cancer cells and other diseased tissues while limiting exposure to healthy tissue.

The company’s leading product candidate is iopofosine I 131, also known as CLR 131, a small-molecule radiopharmaceutical being studied for the treatment of hematologic malignancies, including relapsed or refractory multiple myeloma and certain types of lymphoma.